Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis

Trial Profile

Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs QR 010 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors ProQR Therapeutics
  • Most Recent Events

    • 16 Aug 2017 Preliminary data from single ascending dose cohort of this study were presented at the European Cystic Fibrosis Conference, According to a ProQR Therapeutics media release.
    • 15 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
    • 15 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top